BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35870712)

  • 1. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
    Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer.
    Visani L; Livi L; Ratosa I; Orazem M; Ribnikar D; Saieva C; Becherini C; Salvestrini V; Scoccimarro E; Valzano M; Cerbai C; Desideri I; Bernini M; Orzalesi L; Nori J; Bianchi S; Morandi A; Meattini I
    Radiother Oncol; 2022 Dec; 177():40-45. PubMed ID: 36349599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
    Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
    Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis.
    Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
    Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
    Becherini C; Visani L; Caini S; Bhattacharya IS; Kirby AM; Nader Marta G; Morgan G; Salvestrini V; Coles CE; Cortes J; Curigliano G; de Azambuja E; Harbeck N; Isacke CM; Kaidar-Person O; Marangoni E; Offersen B; Rugo HS; Morandi A; Lambertini M; Poortmans P; Livi L; Meattini I
    Cancer Treat Rev; 2023 Sep; 119():102586. PubMed ID: 37336117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
    Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
    JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
    Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
    Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
    Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.
    Zhao M; Hanson KA; Zhang Y; Zhou A; Cha-Silva AS
    Target Oncol; 2023 May; 18(3):327-358. PubMed ID: 37074594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Alvarez A; Bernal AM; Anampa J
    Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer.
    Kim KN; Shah P; Clark A; Freedman GM; Dastgheyb S; Barsky AR; Dreyfuss AD; Taunk NK
    Breast; 2021 Dec; 60():163-167. PubMed ID: 34653725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
    Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
    Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
    Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
    Takatsuka D; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Iwata H
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e175-e182. PubMed ID: 36085411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.